Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases · people with liver metastases
1 finding from 1 review
Recurrence of liver metastases local progression · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases local progression compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Recurrence of liver metastases distant recurrence · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases distant recurrence compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review
Side effects (tachycardia, agitation, or feed intolerance) leading to a reduction in dose or withholding of methylxanthines№ of participants: 30(1 RCT) · preterm infants
It is very uncertain whether caffeine changes side effects (tachycardia, agitation, or feed intolerance) leading… compared with other methylxanthines (very low certainty).
1 finding from 1 review
RR 0.17 [0.02, 1.32]
Studies not reported
Very low
Recurrence rate of endometriosis · women with endometriosis
It is very uncertain whether pentoxifylline changes recurrence rate of endometriosis compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality ‐ formoterol and budesonide vs salmeterol and fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause non‐fatal serious adverse events ‐ formoterol/budesonide… compared with salmeterol/ICS (low certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in asthma‐related non‐fatal serious adverse events ‐… compared with salmeterol/ICS (low certainty).
5 findings from 1 review
OR 0.69 [0.37, 1.26]
7 studies · 5935 participants
Low
OR 1.01 [0.06, 16.24]
5 studies · 1510 participants
Very low
OR 7 [0.14, 353.37]
1 study · 722 participants
Very low
Show 2 more findings
Mortality (all‐cause) ‐ formoterol versus salbutamol ( · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review
All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone · adults, chronic asthma: all‐cause mortality
Adults: formoterol/ICS showed no clear difference in all‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone compared with salmeterol/ICS (low certainty).
1 finding from 1 review